Literature DB >> 21966106

Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy.

Bratati Singh, Suchismita Panda, Rachita Nanda, Sanghamitra Pati, Manaswini Mangaraj, Pratima Kumari Sahu, Prakash Chandra Mohapatra.   

Abstract

Insulin resistance and the resultant hyperinsulinemia exacerbate the reproductive abnormalities of Polycystic Ovarian Syndrome by increasing ovarian androgen productions and decreasing serum sex hormone binding globulin. The present study was conducted to estimate serum insulin and testosterone level in 44 PCOS cases and 32 control patients. Simultaneously the role of metformin (an insulin sensitizing agent) in modulating insulin resistance and serum androgen level was also analyzed. A significant rise in serum insulin and testosterone (P < 0.001) was observed in cases in comparison to control. Fasting Plasma Glucose to insulin ratio, a marker of insulin resistance revealed a significant fall in PCOS group. Follow up of cases with metformin for 3 months revealed a significant fall in serum insulin (P < 0.05) with improvement in insulin resistance along with a nonsignificant fall in testosterone level. Serum insulin registered a significant positive correlation (P < 0.05) with serum testosterone revealing its etiological association. Thus administration of drugs ameliorating insulin levels is expected to provide new therapeutic modality for PCOS.

Entities:  

Keywords:  Hyperandrogenism; Metformin; Polycystic ovarian syndrome

Year:  2010        PMID: 21966106      PMCID: PMC2994574          DOI: 10.1007/s12291-010-0090-2

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  24 in total

Review 1.  Metformin.

Authors:  C J Bailey; R C Turner
Journal:  N Engl J Med       Date:  1996-02-29       Impact factor: 91.245

Review 2.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 3.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

4.  Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability.

Authors:  L R Boots; S Potter; D Potter; R Azziz
Journal:  Fertil Steril       Date:  1998-02       Impact factor: 7.329

5.  Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.

Authors:  E Diamanti-Kandarakis; C Kouli; T Tsianateli; A Bergiele
Journal:  Eur J Endocrinol       Date:  1998-03       Impact factor: 6.664

6.  Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test.

Authors:  B L Wajchenberg; S S Achando; H Okada; C E Czeresnia; S Peixoto; S S Lima; J Goldman
Journal:  J Clin Endocrinol Metab       Date:  1986-11       Impact factor: 5.958

7.  A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.

Authors:  R S Legro; D Finegood; A Dunaif
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

8.  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

Authors:  E M Velazquez; S Mendoza; T Hamer; F Sosa; C J Glueck
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

9.  Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.

Authors:  R L Barbieri; A Makris; R W Randall; G Daniels; R W Kistner; K J Ryan
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

10.  Insulin resistance in nonobese patients with polycystic ovarian disease.

Authors:  R J Chang; R M Nakamura; H L Judd; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

View more
  7 in total

1.  Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia.

Authors:  Azam Ghaneei; Akram Jowkar; Mohammad Reza Hasani Ghavam; Mohammad Ebrahim Ghaneei
Journal:  Iran J Reprod Med       Date:  2015-02

2.  Protective effects of GABA against metabolic and reproductive disturbances in letrozole induced polycystic ovarian syndrome in rats.

Authors:  Asad Ullah; Sarwat Jahan; Suhail Razak; Madeeha Pirzada; Hizb Ullah; Ali Almajwal; Naveed Rauf; Tayyaba Afsar
Journal:  J Ovarian Res       Date:  2017-09-15       Impact factor: 4.234

3.  Metformin effects on zonulin level in polycystic ovarian women.

Authors:  Manal Ibrahim; Mutaz Ahmeid
Journal:  ADMET DMPK       Date:  2022-12-09

Review 4.  Polycystic Ovary Syndrome: A Disorder of Reproductive Age, Its Pathogenesis, and a Discussion on the Emerging Role of Herbal Remedies.

Authors:  Ling-Hui Zeng; Saba Rana; Liaqat Hussain; Muhammad Asif; Malik Hassan Mehmood; Imran Imran; Anam Younas; Amina Mahdy; Fakhria A Al-Joufi; Shaymaa Najm Abed
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

5.  Co-Administration of Metformin and N-Acetyl Cysteine Fails to Improve Clinical Manifestations in PCOS Individual Undergoing ICSI.

Authors:  Ebrahim Cheraghi; Malek Soleimani Mehranjani; Mohammad Ali Shariatzadeh; Mohammad Hossein Nasr Esfahani; Zahra Ebrahimi
Journal:  Int J Fertil Steril       Date:  2014-07-08

6.  Effect of Metformin-sustained Release Therapy on Low-density Lipoprotein Size and Adiponectin in the South Indian Women with Polycystic Ovary Syndrome.

Authors:  D Rama Nagendra Kumar; Krishna G Seshadri; Monna Pandurangi
Journal:  Indian J Endocrinol Metab       Date:  2017 Sep-Oct

7.  Effect of Metformin on Anthropometric Measurements and Hormonal and Biochemical Profile in Patients with Prediabetes.

Authors:  Mustafa Safiah; Dana Hyassat; Yousef Khader; Oraib Farahid; Anwar Batieha; Mohammed El-Khateeb; Kamel Ajlouni
Journal:  J Diabetes Res       Date:  2021-12-14       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.